Winship Cancer Institute HDR Prostate Brachytherapy Appears Safe Despite Urinary Symptoms

Winship Cancer Institute HRR Prostate Brachytherapy Appears Safe Despite Urinary Symptoms

Winship Cancer Institute of Emory University and team completed a study concluding that high-dose-rate (HDR) prostate brachytherapy is associated with low genitourinary toxicity rates and appears to be safe for men with greater baseline urinary symptoms.

In lay terms, the Winship team has shown that a form of radiotherapy (radiation source) is placed next to the prostate and looks to be benign for the reproductive organ system and safe for men with greater baseline urinary symptoms.

The Study

The Emory University team studied 95 men who were treated there. The men were divided into two groups based on International Prostate Symptom Score (IPSS): less than 15 (79 patients) and 15 or higher (16 patients), and they were compared quality of life outcomes in the groups.

The investigatory team calculated scores based on patient-report symptoms as measured using the IPSS and Expanded Prostate Index for Prostate Cancer-Clinical Practice (EPIC-CP) instruments. EPIC-CP is divided into subdomains, such as urinary incontinence, urinary irritability and obstructive symptoms, reports Prostate Cancer Advisor.

The Results

Baseline, it was reported, IPSS and incontinence and urinary irritation/obstruction scores were greater in the IPSS 15 or higher group that the IPSS less than 15 group as investigators reported in Brachytherapy.  Upon 24 months, scores decreased below baseline and didn’t significantly differ than those with a baseline IPPS less than 15. The mean IPSS had decreased from baseline IPSS less than 15. The mean IPSS had decreased from baseline by 10.7 points in the IPSS 15 or higher group.

Toxicity Incidents

2 patients (12.5%) in the IPSS 15 or higher group did experience a new grade 2 genitourinary toxicity requiring an alpha blocker compared to 21 patients (26.5%) in the IPSS less than 15 group. It turns out not one patient required emergency use of a Foley catheter within 30 days of treatment.

Lead Research/Investigator

Pretesh R. Patel, MD, of the Winship Cancer Institute of Emory University in Atlanta